BACKGROUND: History of substance use disorder (SUD) is associated with risk for prescription opioid misuse in chronic pain patients; however, little data are available regarding risk for prescription opioid misuse within the subgroup of patients with SUD histories. METHODS: Participants with chronic pain, histories of SUD, and current opioid prescriptions were recruited from a single VA Medical Center. Participants (n=80) completed measures of risk for prescription opioid misuse, pain severity, pain-related interference, pain catastrophizing, attitudes about managing pain, emotional functioning, and substance abuse. RESULTS: Participants were divided into three groups based on risk for prescription opioid misuse, as assessed by the Pain Medication Questionnaire (PMQ). Participants in the High-PMQ group reported more pain severity, interference, catastrophizing, depressive symptoms, and lowest self-efficacy for managing pain, relative to the Low-PMQ group; the High-PMQ group and Moderate-PMQ group differed on measures of pain severity, catastrophizing, and psychiatric symptoms (all p-values <0.05). The High-PMQ group had the highest rates of current SUD (32% versus 20% and 0, p=0.009). A regression analysis evaluated factors associated with PMQ scores: pain catastrophizing was the only variable significantly associated with risk for prescription opioid misuse. CONCLUSIONS: Among patients with SUD histories, those with higher risk for prescription opioid misuse reported more pain and impairment, symptoms of depression, and were more likely to have current SUD, relative to patients with lower risk for prescription opioid misuse. In adjusted analyses, pain catastrophizing was significantly associated with risk for prescription opioid misuse, but current SUD status was not a significant predictor. Published by Elsevier Ireland Ltd.
BACKGROUND: History of substance use disorder (SUD) is associated with risk for prescription opioid misuse in chronic painpatients; however, little data are available regarding risk for prescription opioid misuse within the subgroup of patients with SUD histories. METHODS:Participants with chronic pain, histories of SUD, and current opioid prescriptions were recruited from a single VA Medical Center. Participants (n=80) completed measures of risk for prescription opioid misuse, pain severity, pain-related interference, pain catastrophizing, attitudes about managing pain, emotional functioning, and substance abuse. RESULTS:Participants were divided into three groups based on risk for prescription opioid misuse, as assessed by the Pain Medication Questionnaire (PMQ). Participants in the High-PMQ group reported more pain severity, interference, catastrophizing, depressive symptoms, and lowest self-efficacy for managing pain, relative to the Low-PMQ group; the High-PMQ group and Moderate-PMQ group differed on measures of pain severity, catastrophizing, and psychiatric symptoms (all p-values <0.05). The High-PMQ group had the highest rates of current SUD (32% versus 20% and 0, p=0.009). A regression analysis evaluated factors associated with PMQ scores: pain catastrophizing was the only variable significantly associated with risk for prescription opioid misuse. CONCLUSIONS: Among patients with SUD histories, those with higher risk for prescription opioid misuse reported more pain and impairment, symptoms of depression, and were more likely to have current SUD, relative to patients with lower risk for prescription opioid misuse. In adjusted analyses, pain catastrophizing was significantly associated with risk for prescription opioid misuse, but current SUD status was not a significant predictor. Published by Elsevier Ireland Ltd.
Authors: Stephen M Wu; Peggy Compton; Roger Bolus; Beatrix Schieffer; Quynh Pham; Ariel Baria; Walter Van Vort; Frederick Davis; Paul Shekelle; Bruce D Naliboff Journal: J Pain Symptom Manage Date: 2006-10 Impact factor: 3.612
Authors: Beatrix M Schieffer; Quyhn Pham; Jennifer Labus; Ariel Baria; Walter Van Vort; Philip Davis; Frederick Davis; Bruce D Naliboff Journal: J Pain Date: 2005-09 Impact factor: 5.820
Authors: Cara P Holmes; Robert J Gatchel; Laura L Adams; Anna W Stowell; Alyson Hatten; Carl Noe; Leland Lou Journal: Pain Pract Date: 2006-06 Impact factor: 3.183
Authors: Karen O Anderson; Barbara Noel Dowds; Robyn E Pelletz; Thomas W Edwards; Christine Peeters-Asdourian Journal: Pain Date: 1995-10 Impact factor: 6.961
Authors: Timothy J Ives; Paul R Chelminski; Catherine A Hammett-Stabler; Robert M Malone; J Stephen Perhac; Nicholas M Potisek; Betsy Bryant Shilliday; Darren A DeWalt; Michael P Pignone Journal: BMC Health Serv Res Date: 2006-04-04 Impact factor: 2.655
Authors: Gadi Gilam; John A Sturgeon; Dokyoung S You; Ajay D Wasan; Beth D Darnall; Sean C Mackey Journal: Pain Med Date: 2020-02-01 Impact factor: 3.750
Authors: Yasamin Sharifzadeh; Ming-Chih Kao; John A Sturgeon; Thomas J Rico; Sean Mackey; Beth D Darnall Journal: Anesthesiology Date: 2017-07 Impact factor: 7.892
Authors: Patrick H Finan; C Patrick Carroll; Gyasi Moscou-Jackson; Marc O Martel; Claudia M Campbell; Alex Pressman; Joshua M Smyth; Jean-Michel Tremblay; Sophie M Lanzkron; Jennifer A Haythornthwaite Journal: J Pain Date: 2017-09-21 Impact factor: 5.820
Authors: Alexander S Perlmutter; Sarah C Conner; Mirko Savone; June H Kim; Luis E Segura; Silvia S Martins Journal: Soc Psychiatry Psychiatr Epidemiol Date: 2016-11-17 Impact factor: 4.328
Authors: John A Sturgeon; Jennifer M Hah; Yasamin Sharifzadeh; Stephanie K Middleton; Thomas Rico; Kevin A Johnson; Sean C Mackey Journal: Int J Behav Med Date: 2018-04
Authors: Julie R Gaither; Joseph L Goulet; William C Becker; Stephen Crystal; E Jennifer Edelman; Kirsha Gordon; Robert D Kerns; David Rimland; Melissa Skanderson; Amy C Justice; David A Fiellin Journal: J Addict Med Date: 2016 Nov/Dec Impact factor: 3.702